Condition: Richter Syndrome · Chronic Lymphocytic Leukemia · Sponsor: Weill Medical College of Cornell University
This study evaluates the effectiveness and safety of Polatuzumab vedotin plus infusional chemoimmunotherapy containing rituximab, etoposide, prednisone, cyclophosphamide and hydroxydaunorubicin. This is a single arm study. Enrolled patients will receive up to six cycles (21-day cycles) of therapy. While on study, subjects will be monitored weekly until end of treatment, then followed for 52 weeks or until disease progression or discontinuation due to toxicity or death. After completion of the 52-week follow-up/End of study visit, Subjects will be followed for an additional 104 week period, with an assessment occurring every 12 weeks to evaluate survival outcomes and next line of treatments only.
This description comes directly from the study's public registry record.
Amelyn Rodriguez, R.N. · 2127461362 · amr2017@med.cornell.edu
Katherine Greig, R.N. · 2127466738 · kag9156@med.cornell.edu
Always discuss trial participation with your own doctor first.
| Mount Sinai- Icahn School of Medicine | New York, New York, United States | Recruiting |
| Columbia University Medical Center | New York, New York, United States | Recruiting |
| Weill Cornell Medicine | New York, New York, United States | Recruiting |
| Ohio state University | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04679012